Objectives Severe systemic inflammation associated with some stages of COVID-19 and in
fatal cases led therapeutic agents developed or used frequently in Rheumatology being at …

Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating …

Objective To summarise the available information on efficacy and safety of
immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a European …

The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern …

The COVID-19 pandemic has resulted in more than 2 million deaths globally. Two
interconnected stages of disease are generally recognised; an initial viral stage and a …

At the beginning of COVID-19, we underlined that this pandemic was a new challenge for
rheumatologists. On the one hand, it was necessary to clarify the impact of this new viral …

Introduction: While waiting for the development of specific antiviral therapies and vaccines to
effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the …

The outbreak of coronavirus in the world has led to an uncertainty about treatment of
patients with autoimmune disorders because of their weakened immune system coupled …

Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care,
hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in …

Background The course of novel coronavirus disease 2019 (COVID-19) has been of special
concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune …